Movers and SHAKERS
What Do The Recent Developments Mean For electroCore?
electrocore Inc is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Its product gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- A new CEO is appointed. Daniel S. Goldberger is appointed as the new Chief Executive Officer (CEO), effective October 1, 2019. Mr. Goldberger has more than 35 years of experience in the biotechnology and medical technology. He served as CEO in multiple medical device companies, including Repro Medsystems and Xtant Medical Holdings. We believe Mr. Goldberger’s experience in turnarounds and commercial execution in the medical device sector is highly valuable for electroCore.
- Expansion into migraine prevention delayed as FDA requires additional information. FDA has requested more information on the clinical data before approving gammaCore for migraine prevention. gammaCore is approved for the treatment of...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.